About us
Our team
Our science
Radiopharmaceuticals
Our technology
Abstracts & publications
Our pipeline
News
All news
ASX releases
Media releases
Events and presentations
Investors
Share price
Annual reports
Shareholder newsletter
Analyst coverage
Corporate governance
Corporate policies
Contact us
About us
Our team
Our science
Radiopharmaceuticals
Our technology
Abstracts & publications
Our pipeline
News
All news
ASX releases
Media releases
Events and presentations
Investors
Share price
Shareholder newsletter
Analyst coverage
Corporate governance
Corporate policies
Contact us
News
ASX Releases
August 24, 2023
TerThera Terbium-161 isotope supply agreement expanded
Read more
Read more
August 18, 2023
EGM Presentation
Read more
Read more
August 18, 2023
EGM Results
Read more
Read more
July 24, 2023
Dr Sherin Al-Safadi Appointed as Vice President Medical and Corporate Affairs
Read more
Read more
June 13, 2023
Pivalate Educational Webinar 14 June 2023
Read more
Read more
May 29, 2023
FDA Pre-IND Meeting Supports an IND Application for RAD101
Read more
Read more
Load More
MEDIA releases
September 15, 2023
RAD Announces Clinical Data Presentation for 68Ga-Trivehexin (RAD 301), at 2023 EANM Annual Meeting
Read more
Read more
July 27, 2023
RAD Announces F18-Pivalate Brain Glioma Imaging Study Published in Prestigious Peer Reviewed Journal
Read more
Read more
May 2, 2023
Positive new publication for RAD301 platform
Read more
Read more
February 21, 2023
FNN Interview with CEO about RAD's ambition to list on Nasdaq
Read more
Read more
February 16, 2023
Investor Webinar
Read more
Read more
February 14, 2023
RAD CEO interview with Proactive Investors and announcement of Nasdaq listing initiation
Read more
Read more
Load more
Events and Presentations
July 31, 2023
Company Presentation July 2023
Read more
Read more
Sign up to our mailing list.
Receive all the latest news from Radiopharm Theranostics.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please fill out all starred fields.